Bioscience Animal Health PCL (BKK:BIS) EBIT: ฿55 Mil (TTM As of Mar. 2026)


BKK:BIS Bioscience Animal Health PCL BKK:BIS
81 GF Score
Price ฿2.06
GF Value ฿2.87
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Bioscience Animal Health PCL EBIT?

Bioscience Animal Health PCL BKK:BIS +0.98% 81 EBIT is ฿55 Mil as of Mar. 2026. GuruFocus rates BKK:BIS with a GF Score™ of 81/100 and a GF Value™ of ฿2.87 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Bioscience Animal Health PCL's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ฿24 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ฿55 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bioscience Animal Health PCL's annualized ROC % for the quarter that ended in Mar. 2026 was 15.35%. Bioscience Animal Health PCL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 25.22%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bioscience Animal Health PCL's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 14.91%.


Bioscience Animal Health PCL  (BKK:BIS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bioscience Animal Health PCL's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=97.096 * ( 1 - 19.91% )/( (472.969 + 540.563)/ 2 )
=77.7641864/506.766
=15.35 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1257.826 - 438.371 - ( 346.486 - max(0, 443.925 - 1045.808+346.486))
=472.969

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1203.825 - 365.275 - ( 297.987 - max(0, 372.123 - 995.257+297.987))
=540.563

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Bioscience Animal Health PCL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=97.096/( ( (110.608 + max(223.32, 0)) + (109.091 + max(326.84, 0)) )/ 2 )
=97.096/( ( 333.928 + 435.931 )/ 2 )
=97.096/384.9295
=25.22 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(400.483 + 239.562 + 24.929) - (438.371 + 0 + 3.283)
=223.32

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(426.052 + 243.956 + 26.178) - (365.275 + 0 + 4.071)
=326.84

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bioscience Animal Health PCL's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=55.213/370.249
=14.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioscience Animal Health PCL EBIT Related Terms


Bioscience Animal Health PCL EBIT Historical Data

* Premium members only.

The historical data trend for Bioscience Animal Health PCL's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioscience Animal Health PCL EBIT Chart

Bioscience Animal Health PCL Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only 96.54 82.03 68.29 94.84 56.25

Bioscience Animal Health PCL Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.32 25.41 14.39 -8.86 24.27

BKK:BIS vs KHC, GIS: EBIT Comparison

For the Packaged Foods subindustry, Bioscience Animal Health PCL's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioscience Animal Health PCL EV-to-EBIT vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Bioscience Animal Health PCL's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bioscience Animal Health PCL's EV-to-EBIT falls into.


BKK:BIS
81GF Score
Bioscience Animal Health PCL BKK:BIS
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioscience Animal Health PCL EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ฿55 Mil mean?
Bioscience Animal Health PCL (BKK:BIS) has a EBIT of ฿55 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bioscience Animal Health PCL.
Is Bioscience Animal Health PCL's EBIT too high?
Bioscience Animal Health PCL's current EBIT is ฿55 Mil. Overall, Bioscience Animal Health PCL has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioscience Animal Health PCL's EBIT compare to KHC and GIS?
Bioscience Animal Health PCL's EBIT of ฿55 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Consumer Packaged Goods company?
A good EBIT depends on the Consumer Packaged Goods industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bioscience Animal Health PCL. Bioscience Animal Health PCL's current EBIT is ฿55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioscience Animal Health PCL stock overvalued right now?
Based on GuruFocus' analysis, Bioscience Animal Health PCL (BKK:BIS) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿2.87, compared to a current price of ฿2.06 — trading 28.2% below its estimated fair value. The current EBIT is ฿55 Mil. Bioscience Animal Health PCL's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Bioscience Animal Health PCL (BKK:BIS), the current EBIT is ฿55 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioscience Animal Health PCL (BKK:BIS) Overvalued in 2026?

Based on GuruFocus' analysis, Bioscience Animal Health PCL stock appears to be undervalued. The current stock price of ฿2.06 is trading 28.2% below its estimated GF Value™ of ฿2.87. GuruFocus considers Bioscience Animal Health PCL to be Modestly Undervalued.

Key valuation signals for BKK:BIS:

  • EBIT: ฿55 Mil
  • GF Value™: ฿2.87 vs. price of ฿2.06 (28.2% below fair value)
  • GF Score™: 81/100 with 6 warning signs

No single metric tells the full story. See the BKK:BIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bioscience Animal Health PCL Business Description

Address Bond Street Road, No. 479, 4th Floor, Muangthongthani, Bangphut, Pakkret, Nonthaburi, THA, 11120
Bioscience Animal Health PCL along with its subsidiaries is engaged in the manufacturing, import and distribution of pharmaceutical supplies, medical devices, equipment and products for livestock and companion animals (pets). Geographically, the company generates revenue from Thailand, and also has presence in other countries.
81GF Score

Get the complete analysis for BKK:BIS

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿2.06
Price
฿2.87
GF Value